Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 54.3 EUR 0.56% Market Closed
Market Cap: 525.6m EUR

Intrinsic Value

The intrinsic value of one PHN stock under the Base Case scenario is 59.29 EUR. Compared to the current market price of 54.3 EUR, Pharmanutra SpA is Undervalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PHN Intrinsic Value
59.29 EUR
Undervaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Pharmanutra SpA

What is Valuation History?
Ask AI Assistant
What other research platforms think about PHN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is PHN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Pharmanutra SpA.

Explain Valuation
Compare PHN to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about PHN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharmanutra SpA

Current Assets 64m
Cash & Short-Term Investments 15.7m
Receivables 30.8m
Other Current Assets 17.6m
Non-Current Assets 51.6m
Long-Term Investments 297k
PP&E 24.8m
Intangibles 23.9m
Other Non-Current Assets 2.6m
Current Liabilities 31m
Accounts Payable 15.7m
Accrued Liabilities 2.9m
Short-Term Debt 90k
Other Current Liabilities 12.4m
Non-Current Liabilities 23.4m
Long-Term Debt 17m
Other Non-Current Liabilities 6.4m
Efficiency

Free Cash Flow Analysis
Pharmanutra SpA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Pharmanutra SpA

Revenue
175.1m EUR
Cost of Revenue
-5.2m EUR
Gross Profit
169.9m EUR
Operating Expenses
-131.6m EUR
Operating Income
38.3m EUR
Other Expenses
-14.7m EUR
Net Income
23.6m EUR
Fundamental Scores

PHN Profitability Score
Profitability Due Diligence

Pharmanutra SpA's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional 3Y Average ROE
Exceptional ROE
Exceptional ROIC
70/100
Profitability
Score

Pharmanutra SpA's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

PHN Solvency Score
Solvency Due Diligence

Pharmanutra SpA's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
70/100
Solvency
Score

Pharmanutra SpA's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHN Price Targets Summary
Pharmanutra SpA

Wall Street analysts forecast PHN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHN is 82.62 EUR with a low forecast of 74.74 EUR and a high forecast of 89.25 EUR.

Lowest
Price Target
74.74 EUR
38% Upside
Average
Price Target
82.62 EUR
52% Upside
Highest
Price Target
89.25 EUR
64% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for PHN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one PHN stock?

The intrinsic value of one PHN stock under the Base Case scenario is 59.29 EUR.

Is PHN stock undervalued or overvalued?

Compared to the current market price of 54.3 EUR, Pharmanutra SpA is Undervalued by 8%.

Back to Top